Objective: To compare the curative effectiveness of continuous transarterial infusion chemotherapy and systemic venous chemotherapy in treating patients with advanced pancreatic cancer, and to evaluate the value of se...Objective: To compare the curative effectiveness of continuous transarterial infusion chemotherapy and systemic venous chemotherapy in treating patients with advanced pancreatic cancer, and to evaluate the value of selective continu-ous transarterial infusion chemotherapy in treating advanced pancreatic cancer. Methods: Of the 51 patients with advanced pancreatic cancer receiving chemotherapy with gemcitabine and 5-fluorouracil, 25 patients were treated with selective con-tinuous transarterial infusion chemotherapy, 26 were treated with systemic venous chemotherapy, and curative effective-ness was analyzed retrospectively. Curative effectiveness included tumor volume, clinical benefit response (CBR), acute and subacute toxic reactions of antitumor drugs, survival rate and median survival time. Results: The objective effective rate in transarterial group was 32.0% versus 23.1% in systemic group without any significant difference (P = 0.475). Clinical benefit rates in transarterial group and systemic group were 80.0% and 50.0% respectively (P = 0.025). The 6-, 9-and 12-month accumulated survival rates and median survival time in transarterial group were higher than those of the systemic group (P = 0.002), the differences were statistically significant. However, the adverse reactions between the two groups were not statistically significant. Conclusion: Compared with systemic chemotherapy, continuous transarterial infusion chemotherapy with gemcitabine and 5-fluorouracil could improve clinical benefit rate and survival time of patients with advanced pancreatic cancer, it is safe and reliable, and the adverse reactions is less.展开更多
【目的】评价经远桡动脉入路对肝肿瘤患者行肝动脉持续灌注化疗(HAIC)的安全性和舒适性。【方法】纳入中山大学附属第一医院放射介入科行经远桡动脉入路进行HAIC的肝肿瘤患者,患者进行1次股动脉入路和1次远桡动脉入路穿刺置管进行自身...【目的】评价经远桡动脉入路对肝肿瘤患者行肝动脉持续灌注化疗(HAIC)的安全性和舒适性。【方法】纳入中山大学附属第一医院放射介入科行经远桡动脉入路进行HAIC的肝肿瘤患者,患者进行1次股动脉入路和1次远桡动脉入路穿刺置管进行自身交叉对照。患者留置导管于肝动脉内行FOLFOX4方案持续动脉灌注化疗。使用生活质量评分量表比较患者远桡动脉入路和股动脉入路的生活质量评分以及记录手术相关并发症。【结果】共纳入患者18例肝肿瘤患者,其中9例先进行股动脉入路后进行远桡动脉入路HAIC,其余9例则先远桡入路再进行股动脉入路HAIC。dTRA期间,穿刺点血肿2例,穿刺点持续疼痛3例,左手掌麻木1例,均为1~2级手术相关的不良事件。没有发生3~4级手术相关的不良事件。术后超声检查显示近端桡动脉均通畅。dTRA和TFA之间的穿刺时间差异有统计学意义(4分vs.3分,P<0.05)。然而,dTRA的生活质量评分均优于TFA。患者更倾向选择dTRA(7.89 vs.2.72,P<0.001)。dTRA的压迫止血时间比TFA更短(2 h vs.7 h,P<0.05)。【结论】经远桡动脉入路安全可耐受,有利于肝肿瘤患者行持续动脉灌注化疗期间的生活质量和舒适度提升。展开更多
文摘Objective: To compare the curative effectiveness of continuous transarterial infusion chemotherapy and systemic venous chemotherapy in treating patients with advanced pancreatic cancer, and to evaluate the value of selective continu-ous transarterial infusion chemotherapy in treating advanced pancreatic cancer. Methods: Of the 51 patients with advanced pancreatic cancer receiving chemotherapy with gemcitabine and 5-fluorouracil, 25 patients were treated with selective con-tinuous transarterial infusion chemotherapy, 26 were treated with systemic venous chemotherapy, and curative effective-ness was analyzed retrospectively. Curative effectiveness included tumor volume, clinical benefit response (CBR), acute and subacute toxic reactions of antitumor drugs, survival rate and median survival time. Results: The objective effective rate in transarterial group was 32.0% versus 23.1% in systemic group without any significant difference (P = 0.475). Clinical benefit rates in transarterial group and systemic group were 80.0% and 50.0% respectively (P = 0.025). The 6-, 9-and 12-month accumulated survival rates and median survival time in transarterial group were higher than those of the systemic group (P = 0.002), the differences were statistically significant. However, the adverse reactions between the two groups were not statistically significant. Conclusion: Compared with systemic chemotherapy, continuous transarterial infusion chemotherapy with gemcitabine and 5-fluorouracil could improve clinical benefit rate and survival time of patients with advanced pancreatic cancer, it is safe and reliable, and the adverse reactions is less.
文摘【目的】评价经远桡动脉入路对肝肿瘤患者行肝动脉持续灌注化疗(HAIC)的安全性和舒适性。【方法】纳入中山大学附属第一医院放射介入科行经远桡动脉入路进行HAIC的肝肿瘤患者,患者进行1次股动脉入路和1次远桡动脉入路穿刺置管进行自身交叉对照。患者留置导管于肝动脉内行FOLFOX4方案持续动脉灌注化疗。使用生活质量评分量表比较患者远桡动脉入路和股动脉入路的生活质量评分以及记录手术相关并发症。【结果】共纳入患者18例肝肿瘤患者,其中9例先进行股动脉入路后进行远桡动脉入路HAIC,其余9例则先远桡入路再进行股动脉入路HAIC。dTRA期间,穿刺点血肿2例,穿刺点持续疼痛3例,左手掌麻木1例,均为1~2级手术相关的不良事件。没有发生3~4级手术相关的不良事件。术后超声检查显示近端桡动脉均通畅。dTRA和TFA之间的穿刺时间差异有统计学意义(4分vs.3分,P<0.05)。然而,dTRA的生活质量评分均优于TFA。患者更倾向选择dTRA(7.89 vs.2.72,P<0.001)。dTRA的压迫止血时间比TFA更短(2 h vs.7 h,P<0.05)。【结论】经远桡动脉入路安全可耐受,有利于肝肿瘤患者行持续动脉灌注化疗期间的生活质量和舒适度提升。
